Proving the Business Case for the Internet of Things

It’s a boy: First baby born thanks to Ava fertility tracker

Steve Rogerson
August 17, 2017



The first baby conceived using Ava’s fertility tracker bracelet has been born in St George, Utah.
 
Ava is a Swiss medical technology company focused on innovations in women's reproductive health. The fertility tracking sensor bracelet was launched to consumers last summer.
 
Ava user Lizzie McGee, 32, and her husband, Sam, 31, welcomed son Jace McGee, a healthy 3kg boy, on July 11, 2017, becoming the first confirmed "Ava baby" born since the bracelet's official consumer debut. The picture shows the couple with their child.
 
Lizzie, a hairstylist, found out about Ava after struggling for over a year to get pregnant with her second child.
 
"The experience of conceiving our first child was really difficult and stressful on our marriage, and I didn't want to go through the same thing again with our second," said McGee, who conceived Jace after wearing Ava for three months.
 
According to Ava co-founder Lea von Bidder, McGee is one of over one-third of Ava users who purchased the bracelet to aid in conceiving a second child.
 
"Secondary infertility is much more common than many people realise," said von Bidder, "especially in cases where a couple has started their family later in life because it's widely known that fertility decreases as maternal age increases. Ava helps women optimise their chances of conception at any age by identifying in real time her full fertile window, not just the day of ovulation."
 
Since its consumer launch in August 2016, the fertility tracking bracelet has already helped more than 500 women conceive. According to von Bidder, Ava users from across the USA and Europe are reporting about five to ten pregnancies a day.
 
Ava is a sensor bracelet that uses technology to detect precisely the fertile days during a woman's monthly cycle in real time. Worn only at night while sleeping, Ava measures nine physiological parameters including pulse rate, breathing rate, heart rate variability and temperature that, in combination, help indicate a rise in reproductive hormones oestradiol and progesterone. The impact of the rise of these hormones on the physiological parameters is used to detect a 5.3-day fertile window in a woman's cycle.
 
Because users simply wear the Ava bracelet at night and sync it with the Ava app in the morning, they avoid the hassles, mess and invasiveness of other fertility tracking methods such as ovulation strips and BBT thermometers. An FDA Class 1 medical device, the Ava bracelet was proven in a recently concluded clinical study at the University Hospital of Zurich to detect an average of 5.3 fertile days per cycle in real time with 89 per cent accuracy.
 
Founded in Switzerland in 2014 by Pascal Koenig, Philipp Tholen, Peter Stein and Lea von Bidder, Ava is a medical technology company dedicated to bringing innovation to women's reproductive health. Backed by $12.3m in seed and series A funding, Ava has operations in Zurich and San Francisco.